BR112013008355A2 - formas cristalinas do sal de sódio de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético - Google Patents

formas cristalinas do sal de sódio de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético

Info

Publication number
BR112013008355A2
BR112013008355A2 BR112013008355A BR112013008355A BR112013008355A2 BR 112013008355 A2 BR112013008355 A2 BR 112013008355A2 BR 112013008355 A BR112013008355 A BR 112013008355A BR 112013008355 A BR112013008355 A BR 112013008355A BR 112013008355 A2 BR112013008355 A2 BR 112013008355A2
Authority
BR
Brazil
Prior art keywords
pyridin
crystalline forms
ylamino
trifluoromethyl
cyclohexyl
Prior art date
Application number
BR112013008355A
Other languages
English (en)
Inventor
Edwin Bernard Villhauer
Jessica Liang
Mahavir Prashad
Michael J Girgis
Paul Allen Sutton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013008355(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013008355A2 publication Critical patent/BR112013008355A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

formas cristalinas do sal de sódio de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético. a presente invenção refere-se a novas formas cristalinas de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético, sódio, e seu uso no tratamento ou prevenção de uma condição ou um distúrbio associado com a atividade de dgat1 em animais, particularmente, seres humanos. ela também se refere aos processos para fazer tais novas formas cristalinas.
BR112013008355A 2010-10-07 2011-10-05 formas cristalinas do sal de sódio de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético BR112013008355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39088810P 2010-10-07 2010-10-07
PCT/US2011/054841 WO2012047948A1 (en) 2010-10-07 2011-10-05 New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl] -phenyl} - cyclohexyl) -acetic acid

Publications (1)

Publication Number Publication Date
BR112013008355A2 true BR112013008355A2 (pt) 2016-06-14

Family

ID=44802409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008355A BR112013008355A2 (pt) 2010-10-07 2011-10-05 formas cristalinas do sal de sódio de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético

Country Status (25)

Country Link
US (2) US8829194B2 (pt)
EP (2) EP2625172B1 (pt)
JP (1) JP6093703B2 (pt)
KR (2) KR20130115277A (pt)
CN (1) CN103153981B (pt)
AR (1) AR083317A1 (pt)
AU (1) AU2011312185B2 (pt)
BR (1) BR112013008355A2 (pt)
CA (1) CA2813736C (pt)
CL (1) CL2013000929A1 (pt)
CO (1) CO6710909A2 (pt)
EC (1) ECSP13012608A (pt)
ES (2) ES2618411T3 (pt)
GT (1) GT201300089A (pt)
IL (1) IL225532A0 (pt)
MA (1) MA34645B1 (pt)
MX (1) MX2013003835A (pt)
NZ (1) NZ608557A (pt)
PE (1) PE20140337A1 (pt)
PL (2) PL2625172T3 (pt)
PT (2) PT2625172T (pt)
RU (1) RU2612556C2 (pt)
SG (1) SG188586A1 (pt)
TW (1) TW201217360A (pt)
WO (1) WO2012047948A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618411T3 (es) * 2010-10-07 2017-06-21 Novartis Ag Nuevas formas cristalinas de la sal sódica de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclohexil)-acético
CN103796995B (zh) * 2011-09-12 2015-10-07 霍夫曼-拉罗奇有限公司 N-(5-环烷基-或5-杂环基-)-吡啶-3-基甲酰胺
US9108956B2 (en) * 2012-04-27 2015-08-18 Novartis Ag Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors
EA025050B1 (ru) * 2012-04-27 2016-11-30 Новартис Аг Циклические мостиковые простые эфиры в качестве ингибиторов dgat1
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
KR101646716B1 (ko) 2016-02-15 2016-08-08 서성환 조립식 나선계단용 스페이서 및 이를 이용한 조립식 나선계단
BR112021012133A8 (pt) * 2018-12-20 2023-04-11 Merck Sharp & Dohme Forma 1 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, forma 4 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, e, composição farmacêutica

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
BRPI0410779A (pt) 2003-05-20 2006-06-27 Novartis Ag heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma
WO2005097085A1 (en) 2004-04-08 2005-10-20 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
NZ571203A (en) * 2006-03-31 2011-12-22 Novartis Ag Monocyclic heteroaryl-phenyl-cyclohexyl compounds for treating diseases mediated by DGAT-1 activity
RU2009126418A (ru) * 2006-12-11 2011-01-20 Новартис АГ (CH) Способ профилактики или лечения ишемии миокарда
ES2618411T3 (es) * 2010-10-07 2017-06-21 Novartis Ag Nuevas formas cristalinas de la sal sódica de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclohexil)-acético

Also Published As

Publication number Publication date
EP2781516A2 (en) 2014-09-24
CA2813736C (en) 2020-03-24
EP2781516A3 (en) 2014-10-15
NZ608557A (en) 2015-02-27
ECSP13012608A (es) 2013-07-31
CN103153981A (zh) 2013-06-12
CN103153981B (zh) 2017-10-10
ES2618411T3 (es) 2017-06-21
AR083317A1 (es) 2013-02-13
US8829194B2 (en) 2014-09-09
CO6710909A2 (es) 2013-07-15
GT201300089A (es) 2014-12-30
PT2781516T (pt) 2017-03-15
CL2013000929A1 (es) 2013-09-27
RU2612556C2 (ru) 2017-03-09
KR20180011337A (ko) 2018-01-31
AU2011312185B2 (en) 2015-07-02
SG188586A1 (en) 2013-04-30
IL225532A0 (en) 2013-06-27
PT2625172T (pt) 2017-03-10
EP2625172A1 (en) 2013-08-14
RU2013120549A (ru) 2014-11-20
WO2012047948A1 (en) 2012-04-12
MA34645B1 (fr) 2013-11-02
US20140343102A1 (en) 2014-11-20
EP2781516B1 (en) 2016-12-07
JP2013539755A (ja) 2013-10-28
PE20140337A1 (es) 2014-03-13
PL2625172T3 (pl) 2017-07-31
AU2011312185A1 (en) 2013-04-04
JP6093703B2 (ja) 2017-03-08
TW201217360A (en) 2012-05-01
ES2618426T3 (es) 2017-06-21
EP2625172B1 (en) 2016-12-07
KR101900652B1 (ko) 2018-09-19
US20130184311A1 (en) 2013-07-18
PL2781516T3 (pl) 2017-05-31
MX2013003835A (es) 2013-06-28
CA2813736A1 (en) 2012-04-12
KR20130115277A (ko) 2013-10-21

Similar Documents

Publication Publication Date Title
BR112013008355A2 (pt) formas cristalinas do sal de sódio de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
BR112018012894A2 (pt) materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
EA201201648A1 (ru) Стимуляторы sgc
BR112014029967A2 (pt) leitos para animais com baixo teor de poeira e métodos para fabricação dos mesmos
MX341072B (es) Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
BR112013023774A2 (pt) inibidores de glicosilceramida sintase
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
BR112015027536A8 (pt) composição compreendendo bactérias ácidas lácticas para utilização no tratamento preventivo e/ou curativo de cistite recorrente.
BRPI1002601E2 (pt) composição nanoestruturada de uso veterinário para administração de fármacos
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
BR112012004377A2 (pt) terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
CL2015001643A1 (es) Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal.
BR112013022332A2 (pt) métodos para tratamento e/ou prevenção de hiperuricemia ou de um distúrbio metabólico associado com a hiperuricemia, e para melhorar o controle do nível de ácido úrico no sangue, e, composição farmacêutica
BR112015022907A8 (pt) formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila e seus usos
MX2015016057A (es) Solucion estabilizada de acido hipocloroso y uso de la misma.
EP3558330A4 (en) USE OF LACTIC ACID BACTERIA TO TREAT OR PREVENT GESTATIONAL SWEET DIABETES
BR112014009165A2 (pt) sal e uso médico
BR112014032311A2 (pt) sistemas hidráulicos de controle para regular a transferência de fardos
BR112015016370A2 (pt) formas de sais de meglumina de ácido 2-((1r,4r)-4-(-4-(5-(benzoxazol-2-ilamino)piridinila-2-il)fenil)ciclo-hexila) acético e seus usos como inibidores de dgat1
BR112014011508A2 (pt) utilização de pelo menos uma protease estável em meio ácido, e, aditivo e composição para alimentação animal para aves vacinadas
BR112015021271A2 (pt) Agonistas muscarínicos
TN2013000136A1 (en) New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl] -phenyl} - cyclohexyl) -acetic acid
DOP2020000093A (es) Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales
BR112015026672A2 (pt) bactéria de ácido láctico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.